3 unknown, 2 withdrawn. 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow xuna: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML TKI - MMR on 12 Month | Unknown | xuna | 260 | 2022-04-01 | 2022-04-22 | |
| Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT HQP1351( Olverembatinib dimesylate) - Prophylactic HQP1351 Therapy, Third Generation TKI | Phase 2 | Withdrawn | xuna | 2022-01-01 | 2023-01-18 | |
| Belimumab for Treatment of cGVHD Following Allo-HCT Belimumab (Benlysta) - cGVHD | Phase 1 / Phase 2 | Withdrawn | xuna | 2022-01-01 | 2023-01-18 | |
| A Study for PRO of CML in Real Word questionnaire - CML (Chronic Myelogenous Leukemia) | Unknown | xuna | 10000 | 2021-09-22 | 2021-10-25 | |
| Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation comprehensive treatment regimen - Time of Hematopoietic Reconstruction | Not applicable | Unknown | xuna | 30 | 2017-04-20 | 2022-04-15 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Surveys and Questionnaires (1) · belimumab (1) · olverembatinib (1)
China (5)